• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov6
Foghorn Therapeutics released FY2025 Q3 earnings on November 5, 2025 (EST), actual revenue USD 8.153 M (forecast USD 6.197 M), actual EPS USD -0.2514 (forecast USD -0.3328)
04:00
Foghorn Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST) with actual revenue of USD 21.66 M and EPS of USD -0.8359
04:00
Nov5
Foghorn Therapeutics' FHD-909 Begins Phase 1a Clinical Trials for SMARCA4 Mutant Cancers
16:24
Oct30
Foghorn Therapeutics Announces Key Development Program Updates
11:52
Aug6
Foghorn Therapeutics released FY2025 Q2 earnings on August 5 (EST), actual revenue USD 7.557 M (forecast USD 7.097 M), actual EPS USD -0.2847 (forecast USD -0.3585)
03:00
Foghorn Therapeutics released FY2025 Semi-Annual earnings on August 5 (EST), actual revenue USD 13.51 M, actual EPS USD -0.5844
03:00

Schedules & Filings

Schedules
Filings
Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 8.153 M, Net Income -15.85 M, EPS -0.2514

Aug5
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 7.557 M, Net Income -17.94 M, EPS -0.2847

May14
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 5.952 M, Net Income -18.83 M, EPS -0.2996

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More